Enzo Biochem Inc. (NYSE:ENZ) shares dropped 4.6% during mid-day trading on Monday . The company traded as low as $5.16 and last traded at $5.19, with a volume of 133,430 shares changing hands. The stock had previously closed at $5.44.

Separately, Zacks Investment Research upgraded shares of Enzo Biochem from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th.

The stock has a market capitalization of $244.27 million, a P/E ratio of 13.82 and a beta of 1.50. The stock’s 50-day moving average price is $6.12 and its 200-day moving average price is $5.58.

Institutional investors have recently modified their holdings of the stock. Barclays PLC increased its position in shares of Enzo Biochem by 2.3% in the second quarter. Barclays PLC now owns 60,680 shares of the company’s stock valued at $362,000 after buying an additional 1,380 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Enzo Biochem by 3.0% in the first quarter. Geode Capital Management LLC now owns 180,845 shares of the company’s stock valued at $822,000 after buying an additional 5,309 shares during the last quarter. ClariVest Asset Management LLC increased its position in shares of Enzo Biochem by 4.4% in the second quarter. ClariVest Asset Management LLC now owns 265,503 shares of the company’s stock valued at $1,585,000 after buying an additional 11,300 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of Enzo Biochem by 148.5% in the second quarter. BlackRock Advisors LLC now owns 19,949 shares of the company’s stock valued at $119,000 after buying an additional 11,921 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Enzo Biochem by 207.8% in the second quarter. KBC Group NV now owns 20,551 shares of the company’s stock valued at $123,000 after buying an additional 13,875 shares during the last quarter. 54.11% of the stock is owned by institutional investors and hedge funds.

Enzo Biochem Company Profile

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

5 Day Chart for NYSE:ENZ

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.